Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as ...
Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...
A recent study published in Current Molecular Pharmacology reveals that three long non-coding RNAs—HEIH, MIAT, and HOTAIR—are significantly upregulated in Egyptian non-metastatic hepatocellular ...
Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC ...
While new late-stage data point to some liver toxicity signals, analysts at BMO Capital Markets said Tukysa’s efficacy ...
9don MSN
Pancreatic cancer cells 'speak the language' of organs they will later invade, study reveals
Even as they develop at their primary site, pancreatic cancer cells are already expressing the genes that will determine ...
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...
The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...
Recurrent or metastatic nasopharyngeal carcinoma is an aggressive disease, and long-term survival with chemotherapy alone is ...
Ragnhild Langli (70) is the first person in Norway to receive personalized chemotherapy for bowel cancer. She is ...
CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback